Identification

Name
Brexpiprazole
Accession Number
DB09128
Type
Small Molecule
Groups
Approved
Description

Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is approved for the treatment of schizophrenia, and as an adjunctive treatment for major depressive disorder (MDD). Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).

Structure
Thumb
Synonyms
Not Available
External IDs
OPC-34712
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RexultiTablet.25 mg/1OralOtsuka Pharmaceutical Co., Ltd.2015-07-10Not applicableUs
RexultiTablet0.5 mgOralOtsuka Pharmaceutical Co., Ltd.2017-04-19Not applicableCanada
RexultiTablet4 mgOralOtsuka Pharmaceutical Co., Ltd.2017-04-19Not applicableCanada
RexultiTablet2 mg/1OralOtsuka Pharmaceutical Co., Ltd.2015-07-10Not applicableUs
RexultiTablet3 mgOralOtsuka Pharmaceutical Co., Ltd.2017-04-19Not applicableCanada
RexultiTablet1 mg/1OralAvera Mc Kennan Hospital2016-06-17Not applicableUs
RexultiTablet.5 mg/1OralOtsuka Pharmaceutical Co., Ltd.2015-07-10Not applicableUs
RexultiTablet1 mgOralOtsuka Pharmaceutical Co., Ltd.2017-04-19Not applicableCanada
RexultiTablet3 mg/1OralOtsuka Pharmaceutical Co., Ltd.2015-07-10Not applicableUs
RexultiTablet0.25 mgOralOtsuka Pharmaceutical Co., Ltd.2017-04-19Not applicableCanada
Categories
UNII
2J3YBM1K8C
CAS number
913611-97-9
Weight
Average: 433.57
Monoisotopic: 433.182398295
Chemical Formula
C25H27N3O2S
InChI Key
ZKIAIYBUSXZPLP-UHFFFAOYSA-N
InChI
InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)
IUPAC Name
7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}-1,2-dihydroquinolin-2-one
SMILES
O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1

Pharmacology

Indication

As an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Although the mechanism of action of brexpiprazole in the treatment of MDD and schizophrenia is unclear, the efficacy of brexpiprazole may be attributed to partial agonist activity at serotonin 1A and dopamine D2 receptors, and antagonist activity at serotonin 2A receptors.

TargetActionsOrganism
A5-hydroxytryptamine receptor 1A
agonist
partial agonist
Human
AD(2) dopamine receptor
agonist
partial agonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
AAlpha-2C adrenergic receptor
antagonist
Human
AAlpha-1B adrenergic receptor
antagonist
Human
Absorption

Brexpiprazole reaches peak plasma concentration within 4 hours of administration, and steady state occurs within 10-12 days of dosing. Oral bioavailability is 95%, and can be administered with or without food.

Volume of distribution

Intravenous volume of distribution is 1.56L/kg.

Protein binding

>99% protein bound in plasma to serum albumin and α1-acid glycoprotein. Based on in vitro studies, protein binding is not affected by warfarin, diazepam, or digitoxin.

Metabolism

Metabolized mainly by CYP3A4 and CYP2D6 enzymes into its major metabolite, DM-3411. DM-3411 is not considered to contribute any therapeutic effect.

Route of elimination

Approximately 25% urinary and 46% fecal excretion. <1% and ~14% of the unchanged drug was recovered in the urine and feces, respectively.

Half life

Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.

Clearance

19.8mL/h/kg

Toxicity

The most commonly observed adverse effects include: weight increase, akathisia, somnolence, tremor and nasopharyngitis. Neonates are at risk for extrapyramidal and/or withdrawal symptoms if exposed to an antipsychotic drug during the third trimester of development.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Brexpiprazole.Investigational
2,5-Dimethoxy-4-ethylamphetamineBrexpiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineBrexpiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineBrexpiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Brexpiprazole.Experimental
AbirateroneThe serum concentration of Brexpiprazole can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Brexpiprazole.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Brexpiprazole.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Brexpiprazole.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Brexpiprazole.Investigational, Withdrawn
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Brexpiprazole.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brexpiprazole.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Brexpiprazole.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Brexpiprazole.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Brexpiprazole.Approved, Illicit
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Brexpiprazole.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Brexpiprazole.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Brexpiprazole.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Brexpiprazole.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Brexpiprazole.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Brexpiprazole.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brexpiprazole.Approved, Illicit, Investigational
AmiodaroneThe serum concentration of Brexpiprazole can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Brexpiprazole.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Brexpiprazole.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Brexpiprazole.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Brexpiprazole.Experimental
AmphetamineBrexpiprazole may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AprepitantThe serum concentration of Brexpiprazole can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brexpiprazole.Approved, Investigational
ArtemetherThe serum concentration of Brexpiprazole can be increased when it is combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Brexpiprazole.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Brexpiprazole.Approved
AtazanavirThe serum concentration of Brexpiprazole can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Brexpiprazole can be increased when it is combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Brexpiprazole.Investigational, Vet Approved
AzelastineBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Brexpiprazole.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Brexpiprazole.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Brexpiprazole.Illicit
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Brexpiprazole.Investigational
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Brexpiprazole.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Brexpiprazole.Approved
BenzphetamineBrexpiprazole may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Brexpiprazole.Approved
BetaxololThe serum concentration of Brexpiprazole can be increased when it is combined with Betaxolol.Approved
BoceprevirThe serum concentration of Brexpiprazole can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Brexpiprazole can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Brexpiprazole can be decreased when it is combined with Bosentan.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brexpiprazole.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Brexpiprazole.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Brexpiprazole.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Brexpiprazole.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Brexpiprazole.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Brexpiprazole.Approved, Investigational, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Brexpiprazole.Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brexpiprazole.Approved, Investigational
BuprenorphineBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Brexpiprazole can be increased when it is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Brexpiprazole.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brexpiprazole.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Brexpiprazole.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Brexpiprazole.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Brexpiprazole.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Brexpiprazole.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brexpiprazole.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Brexpiprazole.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Brexpiprazole.Investigational
CarbamazepineThe serum concentration of Brexpiprazole can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Brexpiprazole.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Brexpiprazole.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Brexpiprazole.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brexpiprazole.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Brexpiprazole.Experimental
CelecoxibThe serum concentration of Brexpiprazole can be increased when it is combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Brexpiprazole can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Brexpiprazole.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Brexpiprazole.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brexpiprazole.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Brexpiprazole.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brexpiprazole.Approved
ChloroquineThe serum concentration of Brexpiprazole can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brexpiprazole.Approved
ChlorphentermineBrexpiprazole may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Brexpiprazole can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Brexpiprazole.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brexpiprazole.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Brexpiprazole.Approved
CholecalciferolThe serum concentration of Brexpiprazole can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Brexpiprazole.Experimental
CimetidineThe serum concentration of Brexpiprazole can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Brexpiprazole can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brexpiprazole.Approved, Vet Approved
CitalopramThe serum concentration of Brexpiprazole can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Brexpiprazole can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Brexpiprazole can be increased when it is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Brexpiprazole.Approved
ClobazamThe serum concentration of Brexpiprazole can be increased when it is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Brexpiprazole.Investigational
ClomipramineThe serum concentration of Brexpiprazole can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Brexpiprazole.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Brexpiprazole.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Brexpiprazole.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brexpiprazole.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Brexpiprazole.Experimental
ClotrimazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Brexpiprazole can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Brexpiprazole can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Brexpiprazole can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Brexpiprazole.Approved, Illicit
CrizotinibThe serum concentration of Brexpiprazole can be increased when it is combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Brexpiprazole.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brexpiprazole.Approved
CyclosporineThe serum concentration of Brexpiprazole can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brexpiprazole.Approved
DabrafenibThe serum concentration of Brexpiprazole can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Brexpiprazole.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brexpiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Dapoxetine.Investigational
DarifenacinThe serum concentration of Brexpiprazole can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Brexpiprazole can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Brexpiprazole can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Brexpiprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Brexpiprazole can be increased when it is combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Brexpiprazole.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Brexpiprazole.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Brexpiprazole.Approved
DesipramineThe serum concentration of Brexpiprazole can be increased when it is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Brexpiprazole.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Brexpiprazole.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Brexpiprazole.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brexpiprazole.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Brexpiprazole.Approved, Vet Approved
DextroamphetamineBrexpiprazole may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Brexpiprazole.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Brexpiprazole.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brexpiprazole.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Brexpiprazole.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Brexpiprazole.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Brexpiprazole.Experimental
DiethylpropionBrexpiprazole may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Brexpiprazole.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brexpiprazole.Approved, Illicit
DihydroergotamineThe serum concentration of Brexpiprazole can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brexpiprazole.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brexpiprazole.Experimental, Illicit
DiltiazemThe serum concentration of Brexpiprazole can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Brexpiprazole.Approved
DiphenhydramineThe serum concentration of Brexpiprazole can be increased when it is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brexpiprazole.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Brexpiprazole.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Brexpiprazole.Vet Approved
DosulepinThe serum concentration of Brexpiprazole can be increased when it is combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Brexpiprazole.Approved
DoxycyclineThe serum concentration of Brexpiprazole can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Brexpiprazole.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved, Illicit
DronedaroneThe serum concentration of Brexpiprazole can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Brexpiprazole.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Brexpiprazole.Approved
DuloxetineThe serum concentration of Brexpiprazole can be increased when it is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brexpiprazole.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Brexpiprazole.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Brexpiprazole.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Brexpiprazole.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Brexpiprazole.Approved, Investigational
EliglustatThe serum concentration of Brexpiprazole can be increased when it is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Brexpiprazole.Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Brexpiprazole.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Brexpiprazole.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Brexpiprazole.Approved, Investigational
EnzalutamideThe serum concentration of Brexpiprazole can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Brexpiprazole.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Brexpiprazole.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Brexpiprazole.Approved
ErythromycinThe serum concentration of Brexpiprazole can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Brexpiprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Brexpiprazole.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brexpiprazole.Approved
EthanolBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brexpiprazole.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brexpiprazole.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brexpiprazole.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brexpiprazole.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Brexpiprazole.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Brexpiprazole.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brexpiprazole.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Brexpiprazole.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Brexpiprazole.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Brexpiprazole.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Brexpiprazole.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Brexpiprazole.Illicit, Vet Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Brexpiprazole.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Brexpiprazole.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Brexpiprazole.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brexpiprazole.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brexpiprazole.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Brexpiprazole.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Brexpiprazole.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Brexpiprazole.Experimental
FluconazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Brexpiprazole.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Brexpiprazole.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Brexpiprazole.Approved, Illicit
FluoxetineThe serum concentration of Brexpiprazole can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brexpiprazole.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brexpiprazole.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brexpiprazole.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brexpiprazole.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Brexpiprazole.Approved
FluvoxamineThe serum concentration of Brexpiprazole can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Brexpiprazole can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Brexpiprazole can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Brexpiprazole can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Brexpiprazole.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Brexpiprazole.Approved, Investigational
Fusidic AcidThe serum concentration of Brexpiprazole can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brexpiprazole.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Brexpiprazole.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Brexpiprazole.Approved, Illicit, Investigational
GepefrineBrexpiprazole may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Brexpiprazole.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Brexpiprazole.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Brexpiprazole.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Brexpiprazole.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Brexpiprazole.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Brexpiprazole.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Brexpiprazole.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Brexpiprazole.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Brexpiprazole.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Brexpiprazole.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Brexpiprazole.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Brexpiprazole can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Brexpiprazole.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Brexpiprazole.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Brexpiprazole.Approved
HydrocodoneBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brexpiprazole.Approved, Illicit
HydroxyamphetamineBrexpiprazole may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Brexpiprazole.Approved
ImatinibThe serum concentration of Brexpiprazole can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Brexpiprazole can be increased when it is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Brexpiprazole can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Brexpiprazole.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Brexpiprazole.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Brexpiprazole.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Brexpiprazole.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Brexpiprazole.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Brexpiprazole.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Brexpiprazole.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Brexpiprazole.Approved
Iofetamine I-123Brexpiprazole may decrease the stimulatory activities of Iofetamine I-123.Approved
IsavuconazoniumThe serum concentration of Brexpiprazole can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Brexpiprazole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Brexpiprazole.Approved, Vet Approved
IsoniazidThe serum concentration of Brexpiprazole can be increased when it is combined with Isoniazid.Approved
IsradipineThe serum concentration of Brexpiprazole can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Brexpiprazole can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Brexpiprazole.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brexpiprazole.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brexpiprazole.Approved, Investigational
KetoconazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brexpiprazole.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Brexpiprazole.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Brexpiprazole.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Brexpiprazole.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Brexpiprazole.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brexpiprazole.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Brexpiprazole.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brexpiprazole.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Brexpiprazole.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Brexpiprazole.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Brexpiprazole.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Brexpiprazole.Approved
LisdexamfetamineBrexpiprazole may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Brexpiprazole.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Brexpiprazole.Illicit
LopinavirThe serum concentration of Brexpiprazole can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Brexpiprazole.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Brexpiprazole.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Brexpiprazole.Approved
LorcaserinThe serum concentration of Brexpiprazole can be increased when it is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Brexpiprazole.Approved
LovastatinThe serum concentration of Brexpiprazole can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Brexpiprazole.Approved
LuliconazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Brexpiprazole can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Brexpiprazole can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brexpiprazole.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved, Vet Approved
ManidipineThe serum concentration of Brexpiprazole can be increased when it is combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Brexpiprazole.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Brexpiprazole.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Brexpiprazole.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Brexpiprazole.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Brexpiprazole.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Brexpiprazole.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Brexpiprazole.Approved, Investigational
MephedroneBrexpiprazole may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineBrexpiprazole may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brexpiprazole.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brexpiprazole.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Brexpiprazole.Experimental
MequitazineBrexpiprazole may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brexpiprazole.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brexpiprazole.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Brexpiprazole.Approved
MethadoneThe serum concentration of Brexpiprazole can be increased when it is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Brexpiprazole.Approved, Illicit
MethamphetamineBrexpiprazole may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Brexpiprazole.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Brexpiprazole.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brexpiprazole.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Brexpiprazole.Approved
MethotrimeprazineBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brexpiprazole.Approved, Investigational, Vet Approved
MethoxyphenamineBrexpiprazole may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Brexpiprazole.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Brexpiprazole.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Brexpiprazole.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Brexpiprazole.Approved, Investigational
MetoprololThe serum concentration of Brexpiprazole can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosineBrexpiprazole may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Brexpiprazole.Approved, Illicit
MidomafetamineBrexpiprazole may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit, Investigational
MidostaurinThe serum concentration of Brexpiprazole can be increased when it is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Brexpiprazole can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Brexpiprazole.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Brexpiprazole.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Brexpiprazole.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved, Investigational
MirabegronThe serum concentration of Brexpiprazole can be increased when it is combined with Mirabegron.Approved
MirtazapineBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Brexpiprazole.Approved, Investigational
MitotaneThe serum concentration of Brexpiprazole can be decreased when it is combined with Mitotane.Approved
MMDABrexpiprazole may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Brexpiprazole.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Brexpiprazole.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Brexpiprazole.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brexpiprazole.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Brexpiprazole.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Brexpiprazole.Approved, Investigational
NefazodoneThe serum concentration of Brexpiprazole can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Brexpiprazole can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Brexpiprazole can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Brexpiprazole can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Brexpiprazole can be increased when it is combined with Nicardipine.Approved
NilotinibThe serum concentration of Brexpiprazole can be increased when it is combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brexpiprazole.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Brexpiprazole.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Brexpiprazole.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Brexpiprazole.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Brexpiprazole.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brexpiprazole.Approved, Investigational
OlaparibThe serum concentration of Brexpiprazole can be increased when it is combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brexpiprazole.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brexpiprazole.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Brexpiprazole.Approved, Illicit
OrphenadrineBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Brexpiprazole.Investigational
OsimertinibThe serum concentration of Brexpiprazole can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brexpiprazole.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Brexpiprazole.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Brexpiprazole.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Brexpiprazole.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brexpiprazole.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brexpiprazole.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Brexpiprazole can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brexpiprazole.Approved
PanobinostatThe serum concentration of Brexpiprazole can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe serum concentration of Brexpiprazole can be increased when it is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Brexpiprazole can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Brexpiprazole.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brexpiprazole.Approved, Vet Approved
PentobarbitalThe serum concentration of Brexpiprazole can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Brexpiprazole.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Brexpiprazole.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brexpiprazole.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Brexpiprazole.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Brexpiprazole.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Brexpiprazole.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Brexpiprazole.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Brexpiprazole.Experimental
PhenobarbitalThe serum concentration of Brexpiprazole can be decreased when it is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Brexpiprazole.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Brexpiprazole.Approved
PhentermineBrexpiprazole may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe serum concentration of Brexpiprazole can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Brexpiprazole.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Brexpiprazole.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Brexpiprazole.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Brexpiprazole.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Brexpiprazole.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Brexpiprazole.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Brexpiprazole.Approved
PosaconazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleBrexpiprazole may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Brexpiprazole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Brexpiprazole.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Brexpiprazole.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Brexpiprazole.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Brexpiprazole.Approved
PrimidoneThe serum concentration of Brexpiprazole can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Brexpiprazole.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Brexpiprazole.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brexpiprazole.Approved, Vet Approved
PromazineThe serum concentration of Brexpiprazole can be increased when it is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Brexpiprazole.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Brexpiprazole.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Brexpiprazole.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Brexpiprazole.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Brexpiprazole.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Brexpiprazole.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Brexpiprazole.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Brexpiprazole.Investigational
PseudoephedrineBrexpiprazole may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Brexpiprazole.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brexpiprazole.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Brexpiprazole.Approved
QuinidineThe serum concentration of Brexpiprazole can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Brexpiprazole can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Brexpiprazole.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Brexpiprazole.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Brexpiprazole.Approved, Investigational
RanolazineThe serum concentration of Brexpiprazole can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Brexpiprazole.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brexpiprazole.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brexpiprazole.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Brexpiprazole.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Brexpiprazole.Approved, Investigational
RifabutinThe serum concentration of Brexpiprazole can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Brexpiprazole can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Brexpiprazole can be decreased when it is combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Brexpiprazole.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Brexpiprazole.Investigational
RitobegronBrexpiprazole may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Brexpiprazole can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Brexpiprazole.Approved
RolapitantThe serum concentration of Brexpiprazole can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Brexpiprazole.Vet Approved
RopiniroleBrexpiprazole may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brexpiprazole.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Brexpiprazole.Approved, Investigational
RotigotineBrexpiprazole may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Brexpiprazole.Approved
SaquinavirThe serum concentration of Brexpiprazole can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Brexpiprazole.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brexpiprazole.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brexpiprazole.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Brexpiprazole.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Brexpiprazole.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Brexpiprazole.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Brexpiprazole can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brexpiprazole.Approved, Vet Approved
SildenafilThe serum concentration of Brexpiprazole can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Brexpiprazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Brexpiprazole can be increased when it is combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Brexpiprazole.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Brexpiprazole.Investigational
St. John's WortThe serum concentration of Brexpiprazole can be decreased when it is combined with St. John&#39;s Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Brexpiprazole can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brexpiprazole.Approved, Investigational
SulfisoxazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Brexpiprazole.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Brexpiprazole.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Brexpiprazole.Approved, Investigational
SuvorexantBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Brexpiprazole.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Brexpiprazole.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Brexpiprazole.Approved
TelaprevirThe serum concentration of Brexpiprazole can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Brexpiprazole can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Brexpiprazole.Approved
TerbinafineThe serum concentration of Brexpiprazole can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Brexpiprazole.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Brexpiprazole.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Brexpiprazole.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Brexpiprazole.Investigational
ThalidomideBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brexpiprazole.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Brexpiprazole.Approved, Vet Approved
ThioridazineThe serum concentration of Brexpiprazole can be increased when it is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brexpiprazole.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Brexpiprazole.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Brexpiprazole.Approved, Investigational
TiclopidineThe serum concentration of Brexpiprazole can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Brexpiprazole.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Brexpiprazole.Experimental
TipranavirThe serum concentration of Brexpiprazole can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Brexpiprazole.Approved
TocilizumabThe serum concentration of Brexpiprazole can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Brexpiprazole.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Brexpiprazole.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brexpiprazole.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Brexpiprazole.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Brexpiprazole.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brexpiprazole.Experimental
TranylcypromineThe serum concentration of Brexpiprazole can be increased when it is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Brexpiprazole.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Brexpiprazole.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Brexpiprazole.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Brexpiprazole.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brexpiprazole.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Brexpiprazole.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brexpiprazole.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Brexpiprazole.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Brexpiprazole.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Brexpiprazole.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Brexpiprazole.Approved, Investigational
VenlafaxineThe serum concentration of Brexpiprazole can be increased when it is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Brexpiprazole.Experimental
VerapamilThe serum concentration of Brexpiprazole can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Brexpiprazole.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Brexpiprazole.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Brexpiprazole.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Brexpiprazole.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Brexpiprazole.Approved, Investigational
VoriconazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Brexpiprazole.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Brexpiprazole.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Brexpiprazole.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brexpiprazole.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Brexpiprazole.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Brexpiprazole can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Brexpiprazole.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Brexpiprazole.Approved, Investigational
ZolpidemBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Brexpiprazole.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Brexpiprazole.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Brexpiprazole.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brexpiprazole.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Greig SL: Brexpiprazole: First Global Approval. Drugs. 2015 Sep;75(14):1687-97. doi: 10.1007/s40265-015-0462-2. [PubMed:26310190]
  2. Citrome L, Stensbol TB, Maeda K: The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother. 2015 Oct;15(10):1219-29. doi: 10.1586/14737175.2015.1086269. Epub 2015 Sep 24. [PubMed:26402059]
  3. Citrome L: Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015 Sep;69(9):978-97. doi: 10.1111/ijcp.12714. Epub 2015 Aug 6. [PubMed:26250067]
External Links
KEGG Drug
D10309
PubChem Compound
11978813
PubChem Substance
310265043
ChemSpider
10152155
BindingDB
194780
ChEBI
134716
ChEMBL
CHEMBL2105760
PharmGKB
PA166160053
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Brexpiprazole
ATC Codes
N05AX16 — Brexpiprazole
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics
FDA label
Download (943 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentHealthy Adult Males1
1CompletedBasic ScienceSchizophrenic Disorders1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentPsychiatric Disorders / Schizophrenic Disorders1
1CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
1CompletedTreatmentSchizophrenic Disorders3
1Not Yet RecruitingTreatmentAdhd / Autism, Early Infantile / Bipolar I Disorder / Oppositional Defiant Disorder1
1RecruitingHealth Services ResearchSchizophrenic Disorders1
2CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)1
2CompletedTreatmentMajor Depressive Disorder (MDD)3
2CompletedTreatmentSchizophrenic Disorders2
2RecruitingTreatmentPost Traumatic Stress Disorder (PTSD)1
2RecruitingTreatmentStress Disorders, Post-Traumatic1
2, 3CompletedTreatmentSchizophrenic Disorders1
3Active Not RecruitingTreatmentDepressive Disorders / Depressive State / Major Depressive Disorder (MDD) / Moods Disorders / Psychiatric Disorder NOS1
3CompletedTreatmentAcute Schizophrenia3
3CompletedTreatmentAgitation Associated With / Alzheimer's Disease (AD) / Alzheimer's Type / Nervous System Diseases / Psychiatric Disorder NOS2
3CompletedTreatmentDepressive Disorders / Depressive State / Major Depressive Disorder (MDD) / Moods Disorders / Psychiatric Disorder NOS4
3CompletedTreatmentFeeling Anxious / Major Depressive Disorder (MDD)1
3CompletedTreatmentIrritability / Major Depressive Disorder (MDD)1
3CompletedTreatmentMajor Depressive Disorder (MDD)3
3CompletedTreatmentSchizophrenia With Impulsivity1
3CompletedTreatmentSchizophrenic Disorders6
3CompletedTreatmentSleep Disturbances1
3Not Yet RecruitingTreatmentAcute Mania / Bipolar I Disorder1
3RecruitingSupportive CareSchizophrenic Disorders1
3RecruitingTreatmentAcute Manic episode / Bipolar I Disorder2
3RecruitingTreatmentSchizophrenic Disorders1
3TerminatedTreatmentMajor Depressive Disorder (MDD)2
3TerminatedTreatmentPost-Traumatic Stress Disorder (PTSD) / PTSD1
3WithdrawnTreatmentMajor Depressive Disorder and Irritability1
3WithdrawnTreatmentSchizophrenic Disorders1
4Not Yet RecruitingTreatmentDepressive State1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral.25 mg/1
TabletOral.5 mg/1
TabletOral0.25 mg
TabletOral0.5 mg
TabletOral1 mg
TabletOral1 mg/1
TabletOral2 mg
TabletOral2 mg/1
TabletOral3 mg
TabletOral3 mg/1
TabletOral4 mg
TabletOral4 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8349840No2006-04-122026-04-12Us
US8618109No2006-04-122026-04-12Us
US7888362No2007-02-232027-02-23Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00227 mg/mLALOGPS
logP5.38ALOGPS
logP4.65ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)8.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.81 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity129.16 m3·mol-1ChemAxon
Polarizability49.48 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Hydroquinolones / Hydroquinolines / 1-benzothiophenes / Dialkylarylamines / N-alkylpiperazines / Pyridinones / Alkyl aryl ethers / Benzenoids / Thiophenes / Heteroaromatic compounds
show 6 more
Substituents
N-arylpiperazine / Dihydroquinolone / Dihydroquinoline / Quinoline / Benzothiophene / 1-benzothiophene / Dialkylarylamine / Tertiary aliphatic/aromatic amine / Alkyl aryl ether / Pyridinone
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
Partial agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mork A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbol TB, Kikuchi T: Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014 Sep;350(3):589-604. doi: 10.1124/jpet.114.213793. Epub 2014 Jun 19. [PubMed:24947465]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
Partial agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mork A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbol TB, Kikuchi T: Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014 Sep;350(3):589-604. doi: 10.1124/jpet.114.213793. Epub 2014 Jun 19. [PubMed:24947465]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mork A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbol TB, Kikuchi T: Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014 Sep;350(3):589-604. doi: 10.1124/jpet.114.213793. Epub 2014 Jun 19. [PubMed:24947465]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Oosterhof CA, El Mansari M, Blier P: Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014 Dec;351(3):585-95. doi: 10.1124/jpet.114.218578. Epub 2014 Sep 15. [PubMed:25225185]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Oosterhof CA, El Mansari M, Blier P: Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014 Dec;351(3):585-95. doi: 10.1124/jpet.114.218578. Epub 2014 Sep 15. [PubMed:25225185]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Greig SL: Brexpiprazole: First Global Approval. Drugs. 2015 Sep;75(14):1687-97. doi: 10.1007/s40265-015-0462-2. [PubMed:26310190]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Greig SL: Brexpiprazole: First Global Approval. Drugs. 2015 Sep;75(14):1687-97. doi: 10.1007/s40265-015-0462-2. [PubMed:26310190]

Drug created on September 28, 2015 17:01 / Updated on November 14, 2017 08:13